LT3886914T - Antikūnas, apimantis lengvosios grandinės c gale esantį glutamino turintį prailginimą, jo konjugatus ir metodus bei panaudojimo būdus - Google Patents
Antikūnas, apimantis lengvosios grandinės c gale esantį glutamino turintį prailginimą, jo konjugatus ir metodus bei panaudojimo būdusInfo
- Publication number
- LT3886914T LT3886914T LTEPPCT/US2019/062913T LTUS2019062913T LT3886914T LT 3886914 T LT3886914 T LT 3886914T LT US2019062913 T LTUS2019062913 T LT US2019062913T LT 3886914 T LT3886914 T LT 3886914T
- Authority
- LT
- Lithuania
- Prior art keywords
- conjugates
- glutamine
- antibody
- methods
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773708P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/062913 WO2020112588A1 (en) | 2018-11-30 | 2019-11-25 | Antibody comprising a glutamine-containing light chain c-terminal extension, conjugates thereof, and methods and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3886914T true LT3886914T (lt) | 2023-05-25 |
Family
ID=68916605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2019/062913T LT3886914T (lt) | 2018-11-30 | 2019-11-25 | Antikūnas, apimantis lengvosios grandinės c gale esantį glutamino turintį prailginimą, jo konjugatus ir metodus bei panaudojimo būdus |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20220016260A1 (lt) |
| EP (1) | EP3886914B1 (lt) |
| JP (1) | JP7389803B2 (lt) |
| KR (1) | KR20210098488A (lt) |
| CN (1) | CN113453725A (lt) |
| AU (1) | AU2019386945A1 (lt) |
| BR (1) | BR112021010060B1 (lt) |
| CA (1) | CA3121131A1 (lt) |
| CY (1) | CY1126075T1 (lt) |
| DK (1) | DK3886914T3 (lt) |
| EA (1) | EA202191518A1 (lt) |
| ES (1) | ES2943474T3 (lt) |
| FI (1) | FI3886914T3 (lt) |
| HR (1) | HRP20230500T1 (lt) |
| HU (1) | HUE062089T2 (lt) |
| IL (1) | IL283576B2 (lt) |
| LT (1) | LT3886914T (lt) |
| MX (1) | MX2021005874A (lt) |
| PL (1) | PL3886914T3 (lt) |
| PT (1) | PT3886914T (lt) |
| RS (1) | RS64205B1 (lt) |
| SG (1) | SG11202105565UA (lt) |
| SI (1) | SI3886914T1 (lt) |
| WO (1) | WO2020112588A1 (lt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115317603A (zh) | 2016-07-07 | 2022-11-11 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6322996B1 (en) | 1994-08-23 | 2001-11-27 | Drug Delivery System Institute, Ltd. | Protein modification method |
| JP2003527561A (ja) | 1999-01-22 | 2003-09-16 | スミスクライン・ビーチャム・コーポレイション | 蛋白の部位特異的標識化方法およびそのための使用 |
| JP4118462B2 (ja) | 1999-07-19 | 2008-07-16 | 株式会社リコー | 携帯電子機器 |
| EP2829609A1 (en) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| BR0306808A (pt) | 2002-01-09 | 2005-08-30 | Medarex Inc | Anticorpos monoclonais humanos contra cd30 |
| KR101424624B1 (ko) | 2003-05-14 | 2014-07-31 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
| WO2004106939A2 (en) | 2003-06-03 | 2004-12-09 | Paul Scherrer Institut | Method for the linkage of bifunctional chelating agents and (radioactive) transition metal complexes to proteins and peptides |
| JP4680902B2 (ja) | 2003-07-22 | 2011-05-11 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Ｒｇ１抗体及びその使用 |
| KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| PL1691837T3 (pl) | 2003-12-10 | 2012-11-30 | Squibb & Sons Llc | IP-10 przeciwciała i ich zastosowanie |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
| US7778814B2 (en) | 2004-03-30 | 2010-08-17 | Siemens Aktiengesellschaft | Method and device for simulating an automation system |
| AU2006214031A1 (en) | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (PSMA) |
| MX2007009935A (es) | 2005-02-18 | 2007-10-10 | Medarex Inc | Anticuerpos monoclonales que carecen de residuos fucosilo contra antigeno membranal especifico de prostata (psma). |
| LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
| CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP1934261B1 (en) | 2005-09-26 | 2014-10-29 | Medarex, L.L.C. | Human monoclonal antibodies to cd70 |
| WO2007038868A2 (en) | 2005-10-03 | 2007-04-12 | The University Of British Columbia | Novel enediyne compound and uses thereof |
| DK1957539T3 (da) | 2005-12-08 | 2013-05-06 | Medarex Inc | Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse |
| BRPI0620601A2 (pt) | 2005-12-08 | 2011-11-16 | Medarex Inc | anticorpo monoclonal humano isolado ou uma porção ligante ao antìgeno do mesmo, composição, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-o8e e método para tratar ou prevenir uma doença definida pelo crescimento de células tumorais expressando o8e |
| PT1960434E (pt) | 2005-12-08 | 2012-10-02 | Medarex Inc | Anticorpos monoclonais humanos para fucosil-gm1 e métodos para a utilização de anti-fucosil-gm1 |
| PE20080316A1 (es) | 2006-05-25 | 2008-04-10 | Bristol Myers Squibb Co | Compuestos de aziridinil-epotilona |
| PE20080102A1 (es) | 2006-05-25 | 2008-02-11 | Bristol Myers Squibb Co | Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos |
| SG178712A1 (en) | 2006-10-02 | 2012-03-29 | Medarex Inc | Human antibodies that bind cxcr4 and uses thereof |
| MX2009005776A (es) | 2006-12-01 | 2009-06-10 | Medarex Inc | Anticuerpos humanos que se enlazan al cd 22 y sus usos. |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
| JP5868593B2 (ja) | 2007-07-17 | 2016-02-24 | メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． | Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| CN101951946B (zh) | 2007-10-01 | 2014-12-10 | 百时美施贵宝公司 | 结合间皮素的人抗体及其应用 |
| JPWO2010002042A1 (ja) | 2008-07-04 | 2011-12-22 | 国立大学法人九州大学 | タンパク質ラベル化用酵素基質 |
| US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| AU2011239522B2 (en) | 2010-04-15 | 2014-10-23 | Medimmune Limited | Targeted pyrrolobenzodiazapine conjugates |
| AU2011239525B2 (en) | 2010-04-15 | 2015-04-09 | Medimmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| AU2012311505B2 (en) | 2011-09-20 | 2016-09-29 | Medimmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates |
| WO2013092983A2 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| MX350539B (es) | 2012-02-13 | 2017-09-08 | Bristol Myers Squibb Co | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. |
| WO2013181076A1 (en) | 2012-05-30 | 2013-12-05 | University Of Massachusetts Medical School | Coated up-conversion nanoparticles |
| EP3564259A3 (en) | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| RS56169B1 (sr) | 2013-02-14 | 2017-11-30 | Bristol Myers Squibb Co | Jedinjenja tubulisina, metode pripreme i primena |
| US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
| JP6744212B2 (ja) | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | ポリペプチドの酵素的結合 |
| US10195289B2 (en) | 2013-07-31 | 2019-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
| JP6474404B2 (ja) | 2013-08-14 | 2019-02-27 | ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ | ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用 |
| WO2015095972A1 (en) | 2013-12-23 | 2015-07-02 | The Centre For Drug Research And Development | Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
| WO2016115201A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
| BR112017014599A2 (pt) | 2015-01-14 | 2018-01-16 | Bristol-Myers Squibb Company | dímeros de benzodiazepina, conjugados dos mesmos, e métodos de preparação e uso |
| JP2018510864A (ja) | 2015-03-10 | 2018-04-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体 |
| KR20180019592A (ko) | 2015-06-23 | 2018-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | 마크로시클릭 벤조디아제핀 이량체, 그의 접합체, 제조법 및 용도 |
| WO2017025179A1 (en) * | 2015-08-07 | 2017-02-16 | Merck Patent Gmbh | A transglutamine tag for efficient site-specific bioconjugation |
| WO2017059158A1 (en) | 2015-10-02 | 2017-04-06 | Bristol-Myers Squibb Company | Transglutaminase variants for conjugating antibodies |
| KR102493853B1 (ko) | 2016-08-19 | 2023-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법 |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
-
2019
- 2019-11-25 SI SI201930508T patent/SI3886914T1/sl unknown
- 2019-11-25 WO PCT/US2019/062913 patent/WO2020112588A1/en active Application Filing
- 2019-11-25 KR KR1020217019843A patent/KR20210098488A/ko unknown
- 2019-11-25 JP JP2021531116A patent/JP7389803B2/ja active Active
- 2019-11-25 PL PL19821395.1T patent/PL3886914T3/pl unknown
- 2019-11-25 BR BR112021010060-1A patent/BR112021010060B1/pt active IP Right Grant
- 2019-11-25 EP EP19821395.1A patent/EP3886914B1/en active Active
- 2019-11-25 RS RS20230387A patent/RS64205B1/sr unknown
- 2019-11-25 US US17/297,796 patent/US20220016260A1/en active Pending
- 2019-11-25 EA EA202191518A patent/EA202191518A1/ru unknown
- 2019-11-25 MX MX2021005874A patent/MX2021005874A/es unknown
- 2019-11-25 HU HUE19821395A patent/HUE062089T2/hu unknown
- 2019-11-25 HR HRP20230500TT patent/HRP20230500T1/hr unknown
- 2019-11-25 DK DK19821395.1T patent/DK3886914T3/da active
- 2019-11-25 AU AU2019386945A patent/AU2019386945A1/en active Pending
- 2019-11-25 CA CA3121131A patent/CA3121131A1/en active Pending
- 2019-11-25 FI FIEP19821395.1T patent/FI3886914T3/fi active
- 2019-11-25 LT LTEPPCT/US2019/062913T patent/LT3886914T/lt unknown
- 2019-11-25 ES ES19821395T patent/ES2943474T3/es active Active
- 2019-11-25 PT PT198213951T patent/PT3886914T/pt unknown
- 2019-11-25 SG SG11202105565UA patent/SG11202105565UA/en unknown
- 2019-11-25 CN CN201980078228.3A patent/CN113453725A/zh active Pending
-
2021
- 2021-05-30 IL IL283576A patent/IL283576B2/en unknown
-
2023
- 2023-06-02 CY CY20231100264T patent/CY1126075T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020112588A1 (en) | 2020-06-04 |
| CN113453725A (zh) | 2021-09-28 |
| JP2022513686A (ja) | 2022-02-09 |
| EA202191518A1 (ru) | 2021-10-04 |
| BR112021010060B1 (pt) | 2024-03-12 |
| PL3886914T3 (pl) | 2023-05-08 |
| HRP20230500T1 (hr) | 2023-07-21 |
| MX2021005874A (es) | 2021-07-16 |
| HUE062089T2 (hu) | 2023-09-28 |
| AU2019386945A1 (en) | 2021-07-22 |
| CA3121131A1 (en) | 2020-06-04 |
| DK3886914T3 (da) | 2023-07-03 |
| IL283576A (en) | 2021-07-29 |
| IL283576B2 (en) | 2023-07-01 |
| US20220016260A1 (en) | 2022-01-20 |
| ES2943474T3 (es) | 2023-06-13 |
| EP3886914A1 (en) | 2021-10-06 |
| KR20210098488A (ko) | 2021-08-10 |
| IL283576B1 (en) | 2023-03-01 |
| PT3886914T (pt) | 2023-05-05 |
| FI3886914T3 (fi) | 2023-05-26 |
| SG11202105565UA (en) | 2021-06-29 |
| JP7389803B2 (ja) | 2023-11-30 |
| EP3886914B1 (en) | 2023-03-29 |
| SI3886914T1 (sl) | 2023-06-30 |
| CY1126075T1 (el) | 2023-11-15 |
| RS64205B1 (sr) | 2023-06-30 |
| BR112021010060A2 (pt) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500398A1 (en) | Antibody-pyrrolobenzodiazepine derivative conjugate | |
| CY1120849T1 (el) | Αντισωμα που συνδεεται σε ανθρωπινο cd3 | |
| IL273749A (en) | Antibody-vegfr light chain fusion protein | |
| IL277672A (en) | Multivalent antibody | |
| IL276514A (en) | Glypican 3 antibodies and their conjugates | |
| EP3411069A4 (en) | HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF | |
| IL280003A (en) | Anti-mesothelin antibodies | |
| IL283576A (en) | An antibody that contains an extended c-terminal glutamine end and their uses | |
| IL291545A (en) | Antibodies against ctla4, antibody fragments, their immunoconjugates and their uses | |
| EP3596356A4 (en) | COMPOSITE BUCKLE CHAIN | |
| GB201614162D0 (en) | Antibodies, uses thereof and conjugates thereof | |
| PL3723858T3 (pl) | Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim | |
| EP3253793A4 (en) | Anti-surrogate light chain antibodies | |
| EP3902838A4 (en) | CD30 BINDING FRACTIONS, CHEMERA ANTIGEN RECEPTORS AND THEIR USES | |
| EP3589320A4 (en) | CYSTEIN-MUTED ANTIBODIES FOR CONJUGATION | |
| SG11202011232VA (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
| EP3924379A4 (en) | COMMON LIGHT CHAIN ANTIBODIES AND THEIR USES | |
| ZA202005419B (en) | C-terminal antibody variants | |
| EP3738608A4 (en) | NON-NATURAL AMATOXIN TYPE ANTIBODY CONJUGATE | |
| IL308812A (en) | NEODEGRADER-ANTI-CD33 ANTIBODY conjugates | |
| EP4048686A4 (en) | NEW MINI INSULIN WITH EXTENDED C-TERMINAL A-CHAIN | |
| GB202010751D0 (en) | Anti-mesothelin antibodies | |
| GB201708105D0 (en) | Antibodies, uses thereof and conjugates thereof | |
| AU2018903783A0 (en) | Antibody Conjugates and Uses Thereof | |
| GB201820977D0 (en) | Fixaxfx bispecific antibody with commomn light chain |